OSLO, Norway, Feb. 23, 2021 /PRNewswire/ -- Targovax
ASA (OSE: TRVX), a clinical stage immuno-oncology company
developing immune activators to target hard-to-treat solid tumors,
today announces 21-month follow-up data from the randomized phase
I/II trial of ONCOS-102 in combination with standard of care
chemotherapy in malignant pleural mesothelioma (MPM).
The trial is an open label, exploratory phase I/II trial adding
ONCOS-102 to standard of care (SoC) chemotherapy
(pemetrexed/cisplatin) in first and second (and later) line MPM to
assess safety, immune activation and clinical efficacy vs SoC only.
In total, 31 patients have been treated in the trial, with 20
patients in the experimental group receiving the ONCOS-102 and
chemotherapy combination, and 11 patients in a control group
receiving chemotherapy only. The 31 patients have now completed the
21-month follow-up. Immunological data and 12-month survival rate
were reported in June 2020 (see link
here), and 18-month survival follow-up in November 2020 (see link here).
At the 21-month follow-up, half of the patients in the
first-line ONCOS-102-treated group of the randomized part of the
trial were still alive, and mOS was not yet reached. Based on
current survival data mOS will be 20.5 months or longer. For the
first-line SoC-only control group mOS is 13.5 months, which is
similar to outcomes from previously reported trials where patients
received the same chemotherapy treatment1.
Dr. Magnus Jäderberg, Chief Medical Officer of Targovax,
said: "It is most encouraging that survival continues to track
so well in the ONCOS-102-treated first line group. We have earlier
seen and reported how ONCOS-102 drives profound remodeling of the
tumor microenvironment. It is now becoming clear that this is
translating into long-term survival benefit. The survival data also
holds up well to the recently FDA-approved ipilimumab and nivolumab
combination, confirming the relevance of immunotherapy in
mesothelioma and strongly suggesting combining ONCOS-102 with
checkpoint inhibition could further boost efficacy in this highly
malignant and difficult-to-treat cancer."
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz - LHA
Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/continued-survival-benefit-in-targovax-s-oncos-102-trial-in-mesothelioma-at-the-21-month-follow-up,c3293508
View original
content:http://www.prnewswire.com/news-releases/continued-survival-benefit-in-targovaxs-oncos-102-trial-in-mesothelioma-at-the-21-month-follow-up-301233073.html
SOURCE Targovax